Additionally, Stoke stock has a 21-day average true range, or ATR, of 7.16%, indicating volatile daily price swings for the ...

Globally recognized pediatric epileptologist and clinical researcher brings deep expertise in Dravet syndrome and genetic medicine –SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

Mortality rates for Lennox Gastaut syndrome and Dravet syndrome, both developmental epileptic encephalopathies, were ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

Initial safety results for the full cohort of 19 indicated that the treatment was well tolerated. The only notable adverse ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1 year of seizure ...

Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)demonstrate ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...

The MarketWatch News Department was not involved in the creation of this content.-- Phase 3 CDKL5 deficiency disorder (CDD) results: UCB shares 21 scientific abstracts, including ...